Apollo Global Management Ord Shs (APO) Stock Price Today
Aura AI Summary
Key Stats
- $65.96BMarket Cap
- 4,117,199Volume
- FinancialsSector
- $152.7052W High
- $100.3052W Low
- 69 DaysTypical Hold Time
- -$185.53BEnterprise Value
- 2.01%Div Yield
- -Trading Activity
Track Apollo Global Management Ord Shs (APO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Apollo Global Management Ord Shs has traded between a low of $100.3 and a high of $152.7, highlighting its annual price range. Buy and sell Apollo Global Management Ord Shs shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Most Recent News
Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.
Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...

Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.